Elranatamab: Mechanism of Action, Clinical, and Translational Science
Clinical and Translational Science · 2026-05 · 19 (5)
DOI: 10.1111/cts.70554 ↗At a glance
Übersichtsarbeit in Clinical and Translational Science, published online on 2026-04-28. Written by Mohamed Elmeliegy and 10 co-authors. Institution: Oncology Research and Development, Pfizer, Inc., San Diego, California, USA. Major MEDLINE topics: Multiple Myeloma, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized. 34 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Pfizer.
Abstract (original language)
Elranatamab (ELREXFIO) is a humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM). Elranatamab engages CD3 on T cells and B‐cell maturation antigen (BCMA) on myeloma cells to induce T cell–mediated myeloma cell cytolysis. The recommended subcutaneous elranatamab dosing consists of fixed step‐up doses of 12 mg on day 1 and 32 mg on day 4 to mitigate the incidence and severity of cytokine release syndrome (CRS), followed by the full fixed dose of 76 mg once weekly (QW) from weeks 2 to 24. In responders, 76 mg QW is reduced to every 2 weeks (Q2W) after ≥ 6 QW cycles and to every 4 weeks after ≥ 6 Q2W cycles. The full dose (76 mg QW) results in a higher probability of achieving an objective response versus lower doses without worsening the safety profile. This regimen was based on the collective safety, efficacy, pharmacokinetic, and pharmacodynamic data from MagnetisMM‐1, ‐2, ‐3, and ‐9. In the pivotal MagnetisMM‐3 study, in patients with BCMA‐naive RRMM, elranatamab resulted in a 61.0% overall response rate; 37.4% achieved complete response or stringent complete response. Median duration of response was not yet reached; the probability of maintaining response at 30 months was 61.0%. Median progression‐free and overall survival were 17.2 and 24.6 months, respectively. In MagnetisMM‐3 patients, common adverse events (≥ 40%; any grade/grade 3/4) included infections (71.7%/38.5%), CRS (58.8%/0.5%), anemia (53.5%/42.2%), neutropenia (46.0%/44.4%), and diarrhea (42.8%/3.2%). Elranatamab demonstrated deep and durable responses, a manageable safety profile, and low‐grade CRS with predictable timing. Elranatamab is being further evaluated as monotherapy or combination therapy in earlier treatment lines.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Oncology Research and Development, Pfizer, Inc., San Diego, California, USA.
- Oncology Research and Development, Pfizer SLU, Madrid, Spain.
- Oncology Research and Development, Pfizer Inc., Cambridge, Massachusetts, USA.
- Pfizer Research & Development, Pfizer, Inc., San Diego, California, USA.
- Pfizer Research & Development, Pfizer, Inc., South San Francisco, California, USA.
ORCID profiles: Mohamed Elmeliegy, Hoi-Kei Lon, Kamrine Poels
Funding
- Pfizer
Cite
APA
Elmeliegy, M., Viqueira, A., Vandendries, E., Soltantabar, P., Lon, H. K., Poels, K., Shtylla, B., Irby, D., Bompiani-Myers, K., O'Brien, T., & Hibma, J. (2026). Elranatamab: Mechanism of Action, Clinical, and Translational Science. Clinical and Translational Science, 19(5). https://doi.org/10.1111/cts.70554
Vancouver
Elmeliegy M, Viqueira A, Vandendries E, Soltantabar P, Lon HK, Poels K, et al. Elranatamab: Mechanism of Action, Clinical, and Translational Science. Clinical and Translational Science. 2026;19(5). doi:10.1111/cts.70554
BibTeX
@article{Elmeliegy2026,
author = {Elmeliegy, Mohamed and Viqueira, Andrea and Vandendries, Erik and Soltantabar, Pooneh and Lon, Hoi-Kei and Poels, Kamrine and Shtylla, Blerta and Irby, Donald and Bompiani-Myers, Kristin and O'Brien, Thomas and Hibma, Jennifer},
title = {Elranatamab: Mechanism of Action, Clinical, and Translational Science},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {5},
doi = {10.1111/cts.70554}
}
EUVIMED